Xeris Biopharma Holdings XERS Ratios (2020-2026)

NASDAQ XERS
$9.87 -0.11 (-1.10%)
As of: Sep 30, 2026 · 9:53 AM EDT
Reported Financials

Xeris Biopharma Holdings Quarterly Ratios

Periods 24 quarters
Latest Jun 2026

Xeris Biopharma Holdings reported a gross margin of 86.41% and a net margin of -33.77% for the quarter ended Jun 2026. These financial ratios cover 24 quarters of results from Sep 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Ratios Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Profitability
Gross Margin
70.89%77.19%71.58%80.99%82.30%81.02%83.98%80.12%83.03%82.95%85.31%83.79%74.95%84.23%85.48%83.37%85.22%87.24%87.28%86.41%
EBT Margin
-235.16%-237.02%-154.59%-104.81%-74.58%-40.03%-50.71%-53.98%-25.93%-30.70%-45.95%-29.66%-35.13%-8.51%-15.34%-2.70%0.83%12.91%2.69%-33.77%
EBIT Margin
-220.24%-225.26%-131.72%-74.75%-63.18%-45.77%-40.00%-42.04%-10.17%-22.17%-35.05%-17.03%-23.76%2.79%-5.14%6.27%9.05%19.55%9.52%5.62%
EBITDA Margin
-217.31%-221.06%-117.98%-62.65%-52.85%-36.48%-30.73%-33.90%-3.75%-15.28%-27.58%-10.81%-18.20%7.83%-0.11%10.51%13.15%23.10%13.19%8.91%
Operating Margin
-220.24%-225.26%-131.72%-74.75%-63.18%-45.77%-40.00%-42.04%-10.17%-22.17%-35.05%-17.03%-23.76%2.79%-5.14%6.27%9.05%19.55%9.52%5.62%
Net Margin
-235.16%-237.02%-152.74%-103.47%-73.44%-39.01%-50.71%-52.20%-25.23%-30.16%-46.71%-31.22%-29.00%-8.51%-15.34%-2.70%0.83%12.91%2.69%-33.77%
FCF Margin
-204.44%-135.69%-219.31%-81.44%-59.73%-48.63%-78.74%-36.16%-30.24%16.83%-49.96%-21.53%-15.30%3.29%-16.69%0.25%24.78%23.36%11.87%8.97%
Efficiency
Inventory AverageInventory Avg.
16.18M17.50M17.38M19.00M22.43M26.89M32.79M37.34M38.49M39.86M41.93M44.05M46.65M50.43M59.99M67.37M68.07M71.45M77.58M
Assets AverageAssets Avg.
217.81M320.99M328.12M310.82M323.77M332.94M325.07M328.28M325.19M329.61M334.17M326.42M322.08M319.26M325.07M352.44M376.86M387.77M401.96M
Equity AverageEquity Avg.
8.71M46.38M95.84M85.20M64.49M50.11M37.62M21.84M8.75M-1.46M-7.98M-14.23M-23.80M-28.97M-32.37M-27.22M-10.08M6.41M13.35M1.64M
Invested CapitalInvested Cap.
184.15M-13.27M202.49M194.64M199.32M218.61M234.02M234.24M242.86M
Asset Utilization RatioAsset Util.
0.230.200.240.320.340.360.410.470.500.520.540.570.630.700.760.760.770.810.83
Leverage & Solvency
Interest Coverage RatioInterest Cover
-13.53-26.82-8.26-5.49-4.70-3.47-2.14-2.45-0.72-1.40-2.03-1.02-1.650.22-0.420.610.922.341.150.74
Debt Ratio
0.590.050.720.730.650.590.570.560.61
Times Interest Earned
-13.53-26.82-8.26-5.49-4.70-3.47-2.14-2.45-0.72-1.40-2.03-1.02-1.650.22-0.420.610.922.341.150.74
Valuation
Price to EarningsP/E
0.00M83.35
Price to SalesP/S
4.594.675.472.622.151.641.842.701.681.981.911.852.272.493.853.065.064.473.184.10
Price to BookP/B
2.433.602.833.854.017.4526.5166.4495.3276.92
Enterprise Value
69.94M129.12M214.81M97.82M118.67M59.28M128.68M280.92M190.83M252.16M240.22M257.54M355.26M434.94M798.08M693.63M1,255.80M1,193.75M889.09M1,253.10M
EV to EBIT
128.1247.9524.7634.24
EV to EBITDA
304.0957.2532.2218.4925.69
Market Capitalization
162.92M231.55M346.96M209.37M212.10M181.24M223.78M361.59M256.81M324.61M327.58M335.11M424.66M506.57M856.52M752.92M1,347.40M1,304.79M1,000.84M1,374.85M
Price to FCFP/FCF
127.6245.5820.6224.29
EV to FCF
118.9441.7018.3222.14
EV to CFO
118.9441.7018.3222.14
Return Ratios
Return on Sales [ROS]ROS
-220.24%-225.26%-131.72%-74.75%-63.18%-45.77%-40.00%-42.04%-10.17%-22.17%-35.05%-17.03%-23.76%2.79%-5.14%6.27%9.05%19.55%9.52%5.62%
Return on Capital Employed [ROCE]ROCE
-82.98%-50.09%-45.76%-47.49%-32.76%-26.30%-25.76%-20.45%-19.13%-17.53%-14.37%-19.19%-15.18%-10.03%-4.27%4.15%9.31%13.34%17.23%
Return on Invested Capital [ROIC]ROIC
-34.15%-10.71%-4.52%
Return on Assets [ROA]ROA
-56.34%-43.00%-41.66%-42.64%-29.24%-23.36%-21.98%-18.82%-19.14%-19.54%-17.82%-19.33%-17.03%-14.12%-9.84%-4.44%0.15%3.10%-4.27%
Return on Equity [ROE]ROE
-1,076.40%-264.58%-144.01%-160.45%-205.48%-188.89%-206.77%-327.03%-705.99%8.64%89.95%-1,047.60%

Xeris Biopharma Holdings Ratios API

Pull Xeris Biopharma Holdings's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=XERS&statement=Ratios&frequency=Quarter&period=all&api_key=YOUR_API_KEY